143 results about "Splenic lymphocyte" patented technology

The invention provides a novel immunomodulatory protein FIP-ppl derived from a fungus by applying a genetic engineering means for the first time. According to the invention, a gene which codes the protein is provided and synthesized. The protein FIP-ppl has immunomodulatory and anti-tumor effect. Experiments verify that the protein has a catalytic splitting effect on splenic lymphocyte and can add synthesis of interleukin 2; the protein has remarkable suppress proliferation and apoptosis-inducing effects of the protein on hepatoma carcinoma cell HepG2 and gastric carcinoma cell MCG823 are further verified. The protein FIP-ppl provided by the invention is lowly homological with almost found immunomodulatory proteins of fungi and is a novel immunomodulatory and anti-tumor biological preparation.

The invention discloses a clam bioactive peptide and its extraction method and use. The clam bioactive peptide has an N-tail end sequence of TRGIDEIQNT GGGGTRR, an isoelectric point of 8.79 and molecular weight of 18KDa. The clam bioactive peptide can promote macrophage phagocytosis activity and splenic lymphocyte propagation capability of an immunization system, has pharmacological effects of improving immunity, can be used for preparation of a drug or a health food for improving immunity and has potential of exploitation of novel immunopotentiation drugs.

The invention discloses immunopeptide freeze-dried powder and a preparation method thereof, belongs to the technical fields of deep-processing of agricultural products and comprehensive utilization of by-products thereof, and relates to immunopeptide freeze-dried powder and a preparation method thereof. With any one of corn gluten meal, wheat protein powder, rice protein powder, soyabean protein powder, mung bean protein powder and poultry and egg white powder as a raw material, a process route comprising superfine grinding of designed raw material, blending and homogenizing of a protein solution, controlled enzymatic hydrolysis under an environment of a high-voltage pulsed electric field, low-temperature enzyme deactivation, low-temperature centrifugation, low-temperature membrane separation and vacuum freeze drying is realized, wherein the moisture content of the raw material is 1.0-5.0% and the protein content of the raw material is 40-70%; the immunopeptide freeze-dried powder of which the moisture content is 1.2-1.8%, the protein content is 72-86% and the molecular weight is 10-30 kDa is obtained. Compared with a control group, an immune activity evaluation experiment proves that the multiplication capacity of splenic lymphocyte of mice of an experimented group is significantly improved.

This invention provides a method for establishing hetero-hybrid tumor engineering cell sequence for producing human monoclonal antibody for anti-hepatitis B virus. The anti-HBs positive human splenic lymph cell (SL) is fused with mouse plasmacytoma sequence P3-X63 / Ag8-653 cell. Limiting dilution method is used for cloning the positive antibody poro-hybrid-tumor cell to obtain hetero hybrid tumor engineering cell sequence which produces human monoclonal antibody for anti-hepatitis B virus, with stable and high product, rate. Said monoclonal antibody is proceeded with purification and cross-linkage with interferon to produce target prepn. of anti-hepatitis B virus human monoclonal antibody crosslinking with itnerferon, and passive immune prepn. for hepatitis B, and testing agent for hepatitis B.

The invention discloses a recombination Staphylococcus aureus enteritis toxin E with SEQ ID NO.1 amino acid sequence, which is composed of pGEX-4T-1 and SEQ ID NO.2 nucleotide sequence. The invention utilizes hyperantigen activity to accelerate the breeding of splenocyte and inhibit tumour from growing, which is fit for preparing high-purity enterotoxin and hyperantigen agent.

The present invention relates to THE archaeological detection field, and discloses a method for preparing a tussah silk fibroin protein monoclonal antibody, a FeCl2 and tetrasodium iminodisuccinate mixed solution system is used for extraction of tussah silk fibroin, the tussah silk fibroin as a complete antigen is injected into the body of rabbits, a rabbit with high immunizing potency is selected, splenic lymphocytes and myeloma cells of the rabbit with the high immunizing potency are fused, after obtained hybridoma is cultured, a bacterial strain with positive secreted antibodies, strong antibody secreting ability and good cell growth conditions can be selected by indirect ELISA method, the bacterial strain is cloned by limiting dilution method until the secreting positive rate of the antibody with grown hybridoma is 100%, the selected cells are used for large-scale production, and then a chromatographic column is used for purification of the monoclonal antibody. The antibody prepared by the method has strong specificity, and in the application process, the operation is simple and quick, and the detection accuracy is high.

The invention relates to 6 saturated fatty chain alcohol Glu-Asp-Gly tripeptide ester conjugates with immunosuppressive activity in a general formula Glu-Asp-Gly-O-CH2-(CH2)nCH3 I. In saturated fatty chain alcohol, n is equal to 6, 8, 10, 12, 14 or 16. The invention also relates to a preparation method and application of the conjugates as an immunosuppressant. An experimental result of the saturated fatty chain alcohol Glu-Asp-Gly tripeptide ester has the inhibition effects of splenic lymphocyte mitogen breeder reaction and macrophage phagocytosis activity indicates that the conjugates of the invention have excellent immunosuppressive action and can be clinically used as an immunosuppressant.

The invention belongs to the field of detection of harmful biological molecules in food, and relates to a preparation method and application of an Aspergillus flavus specific single-chain antibody. The cell wall proteins of the Aspergillus flavus hypha are used for immunizing chickens and mice respectively; messenger RNA of chicken splenic lymphocytes after immunization are extracted; a chicken source single-chain antibody library is constructed; a phage display technology is employed to screen the library to obtain an Aspergillus specific single-chain antibody gene with high affinity to Aspergillus flavus. The antibody gene is subcloned into an expression vector of an alkaline phosphatase protein, and expressed and purified in Escherichia coli, so as to obtain a fusion protein and a hybridoma cell 2A8 secreting Aspergillus flavus specific monoclonal antibody. The monoclonal antibody as a capture antibody and AfSA4-AP fusion protein as a detection antibody are employed to establish a SandWich ELISA immunological detection system for detecting Aspergillus flavus contamination in crops and stored plant-derived products.

The invention discloses the application of cyclocarya paliurus extract in the preparation of a medicament for preventing and treating leukemia. High-content cyclocarya paliurus extract is obtained by performing the purification treatment combined of water extraction, ethanol extraction, membrane dialysis, and gel chromatographic column on cyclocarya paliurus leaves. The cyclocarya paliurus extract contains 90 to 98 percent of polysaccharide; killing activity detection experiments show that the cyclocarya paliurus extract can be used for improving the activity of the splenocytes for killing human leukemia cells K652 in vitro; the killing multiples can reach 2.47 to the maximum. After granules, tablets, buccal tablets, capsules, pills, powder injection or oral liquid prepared by adding certain additives into the cyclocarya paliurus extract disclosed by the invention are orally taken, the effects of preventing and treating the leukemia can be achieved.

The invention relates to conjugates of saturated aliphatic chain alcohol, dexamethasone, and Glu-Asp-Gly, preparation, a nano structure, and applications thereof. The invention discloses 6 saturated aliphatic chain alcohol modified dexamethasone-Glu-Asp-Gly conjugates represented by the formula 10 a-f, wherein in the formula the n represents 7, 9, 11, 13, 15, or 17. The invention also discloses a preparation method, a nano structure, immunity inhibition activity, inflammation inhibition activity, and pain relieving activity of the conjugates. The invention also finds that the conjugates do not have any side effect leading to osteoporosis. The researches on the inhibition effect of the conjugates on splenic lymphocyte mitogen proliferation reactions and the survival time after mouse retroauricular cardiac muscle transplant show that the conjugates have an excellent immunity inhibition effect. The researches on the effect of the conjugates on the swelling degree of mouse ears which are inflamed due to xylene show that the conjugates have an excellent anti-inflammation effect. The researches on the effect of the conjugates on mouse heat radiation tail flick time show that the conjugates have an excellent pain-relieving effect. The researches on the effect of the conjugates on the mouse thigh bones show that the conjugates cannot cause osteoporosis. So the conjugates have a wide application prospect in the preparation of immunity inhibition drugs.

The present invention provides a kind of recombinant staphylococcus aureus enterotoxin I prepared through genetic engineering process, and the protein is one kind of super antigen with the amino acid sequence of SEQ ID No. 1. The recombinant plasmid is reconstructed with pGEX-4T-1 and the nucleotide sequence of SEQ ID No. 2. Extracorporeal experiment shows that the prepared high purity recombinant SEI protein can excite the splenic lymphopoiesis of mouse effectively in dosage depending relationship and the excited splenic lymphocyte of the mouse has obvious tumor cell killing effect. Compared with available staphylococcus aureus enterotoxin C as the main effective component in the staphylococcus aureus filtrate preparation, the recombinant SEI protein has even high super antigen activity and may be prepared into super antigen preparation for inhibiting tumor growth effectively.

The invention relates to the field of archaeological detection and discloses a preparation method of a bombyx mori silk fibroin monoclonal antibody. The preparation method comprises the following steps: extracting bombyx mori silk fibroin by adopting an isooctane, n-octyl alcohol, bi(2-ethylhexyl) sodium sulfosuccinate and polyvinyl pyridine quaternary ammonium salt mixed system, injecting the bombyx mori silk fibroin serving as a complete antigen into the bodies of rabbits, selecting the rabbits with high immunizing potency, fusing splenic lymphocytes and myeloma cells, cultivating the obtained hybridoma cells, selecting strains with positive secretory antibodies, high secretion ability and good cell growth state by an indirect ELISA method, cloning by a limited dilution method until the antibody secretion positive rate of hybridoma cell growth is 100 percent, performing big turn production on the screened cells, and purifying the obtained monoclonal antibody by a chromatographic column. The antibody prepared by the method has high specificity, and is simple and rapid in operation during the application process and high in detection accuracy.

The invention relates to an Antarctic cold-adapted microbial extracellular polysaccharide capable of improving body immunity, and belongs to the technical field of medicaments and health-care food. The cold-adapted microbial extracellular polysaccharide is prepared by culturing, fermenting, separating and purifying Antarctic cold-adapted bacteria (Pseudoaltermonas sp.) S-5, the strain collection number of which is CGMCC NO.3433. The molecular weight of the polysaccharide is 39,7046Da, and the polysaccharide consists of mannose, dextrose and galactose in a molar ratio of 4.8: 50.9: 44.3. The prepared Antarctic cold-adapted microbial extracellular polysaccharide capable of improving the body immunity can promote the proliferation of in vitro spleen lymphocytes, enhance the activity of macrophages and improve the body immunity.

The invention provides oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicine. In in-vitro cell experiments, oligomerization mannuronic acid can obviously promote forming of colony-forming unit-granulocyte macrophage (CFU-GM), simultaneously can promote marrow stroma cells to breed and secrete CFU-GM and promote splenic lymphocytes to secrete interleukin-3. In vivo experiments further indicates that oligomerization mannuronic acid can obviously restrain reduction of white blood cells in mice caused by cyclophosphamide, increase the number marrow nucleated cell of the mice and promote forming of CFU-GM. Experiment results indicate that oligomerization mannuronic acid can be developed to be a clinical medicine capable of effectively preventing leucopenia.

The invention relates to an aeromonas hydrophila micro-capsular oral vaccine, which belongs to the technical field of biological pharmacy. The aeromonas hydrophila micro-capsular oral vaccine is prepared by using sodium alga acid and chitosan as wall materials, using the inactivated bacteria of aeromonas hydrophila as a core material and by using improved atomization and ion crosslinking technology. When the aeromonas hydrophila sodium alga acid-chitosan micro-capsular oral vaccine is used for immunizing a mouse and crucian, the phagocytosis activities of macrophages, the conversion efficiency of the splenic lymphocytes and the expression amount of cell factors such as IFN-gamma and Il-4 of the mouse and the crucian can be improved obviously. The relative protection rate of the vaccine for the crucian is 39.3 percent. A microcapsule is stable in a simulated gastrointestinal environment and shows high burst release and slow release; and the bacterial antigenicity of the microcapsule is well maintained and the vaccine has high safety and high storage stability.

The invention relates to a mimic eptitope peptide of BAFF-R and a DNA coding the peptide and the application of the mimic eptitope peptide in the preparation of antitumor bacterins and drugs. The mimic eptitope of 7 amino acids of BAF-R is a mimic eptitope of molecule BAFF-R with high affinity with a monoclonal antibody of BAFF-R, and is obtained through selection from a phage random display 7-peptide bank with a monoclonal antibody of BAFF-R as the antigen, wherein the sequence of the amino acids is Gly Tyr Thr Arg Trp Gly Cys. The 7-amino-acid mimic eptitope can also be used to construct a poly-peptide vaccine. The clonal inhibition rates of the phage display peptide provided by the invention are all more than 50 percent, and can specifically inhibit the combination between antibody and antigen for a larger extent, greatly improve the proliferation of mouse spleen lymphocytes without adjuvant, the mimic antigen is good in immunogenicity, as illustrated by the induced cell immune response after mice are vaccinated with the mimic antigen.

The present invention provides process of preparing recombinant staphylococcus aureus enterotoxin O, as one kind of superantigen with the amino acid sequence as shown in SEQ ID No. 1. The present invention constructs one kind of recombinant plasmid for expression staphylococcus aureus enterotoxin O via recombining pGEX-4T-1 and the polynucleotide sequence of SEQ ID No. 1, and obtains initial fusion GST-SEO protein accounting for 15-25 % of total bacterial protein content. The present invention utilizes the recombinant staphylococcus aureus enterotoxin O with superantigen activity in promoting extracorporeal spleen lymphopoiesis and inhibiting extracorporeal tumor cell growth. It is proved that the recombinant staphylococcus aureus enterotoxin O has superantigen activity similar to that of SEC. The present invention is suitable for use in preparing high purity enterotoxin with superantigen activity and developing superantigen preparation.

The invention discloses porcine reproductive and respiratory syndrome virus M protein CTL cell epitopes and application thereof. The identification of the epitopes comprises the following steps of: fusing and cloning a M protein gene of a porcine reproductive and respiratory syndrome virus CH-1a strain and a mouse ubiquitin gene to form a DNA vaccine and also form recombination viruses, expressing an M protein, of a WR strain vaccinia virus; immunizing a BALB / c mouse according to a Priming-Boosting policy, separating the mouse splenic lymphocyte, culturing and stimulating a CTL short peptide in vitro predicted and synthesized by a bioinformatic method, and using the flow cytometry and enzyme-linked immunospot technology to identify two CTL epitopes that are K93FITSRCRL and F57GYMTFVHF. The identification of the PRRSVM protein CTL cell epitopes lays a certain theoretical foundation for the PRRS cell immune mechanism and the novel epitope pepetide vaccine and has an instructing significance for the theoretical study on PRRS preventing and control technology.

The invention provides universal CD8+T cell epitope polypeptide of a chicken IBV (Infectious Bronchitis Virus) S1 protein, and belongs to the field of gene and protein engineering. The epitope polypeptides are prepared by the following steps: screening 21 epitope polypeptides in accordance with binding motif sequences in amino acid sequences of the S1 genes of the IBV virus according to the binding motif sequences of haplotype chicken major histocompatibility complex (MHC) I-type molecules; then, taking lymphocytes of three constructed SPF (Specific Pathogen Free) chicken immunized by DNA (Deoxyribonucleic Acid) recombinant plasmids of the S1 genes containing different subtype IBVs, determining the capacity of the 21 polypeptides which induce chicken splenic lymphocytes to secrete interferon-gamma by using an ELIspot (Enzyme-Linked Immunospot Assay) method, and finally, screening to obtain four universal functional T cell epitope polypeptides of IBV, wherein the sequences are respectively shown in SEQ ID NO. 1-4. The four epitope polypeptides provided by the invention are combined in use to prepare a universal vaccine for IBV. The invention further provides a method for screening the epitope of the functional T cell of the S1 protein of the IBV.

The invention relates to an anti-echinococcosis antigen monoclonal antibody hybridoma cell strain, an anti-echinococcosis antigen monoclonal antibody and application of the anti-echinococcosis antigenmonoclonal antibody. The anti-echinococcosis antigen monoclonal antibody hybridoma cell strain is classified and named as a hybridoma cell strain XJ10D8D10. The strain is preserved in the China Center for Type Culture Collection (CCTCC) on September 25th, 2017. The preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C201789. According to the invention,an echinococcosis adult surface membrane antigen is extracted; a Balb / c mouse is immunized; splenic lymphocytes secreting anti-echinococcosis adult surface membrane antigen are obtained; the hybridoma cell strain secreting the anti-echinococcosis adult surface film antigen is obtained by fusing the splenic lymphocytes with SP2 / 0 cells, so that an echinococcosis-resistant adult surface film antigen antibody is obtained, and the echinococcus granulosus infection of dogs can be sensitively detected through fecal antigen detecting by using the antibody as a diagnostic reagent. And necessary conditions are provided for preparation of large-scale general survey detecting kits.

The invention relates to a lactobacillus rhamnosus strain 1.0320 with an immunomodulatory effect and application of the lactobacillus rhamnosus strain 1.0320. The lactobacillus rhamnosus strain 1.0320is applied to the fermentation process of yoghourt or pickles or used for preparing freeze-dried bacterial powder. According to the lactobacillus rhamnosus, the intestinal wall adhesion rate is high(up to 11.76% or above), the lactobacillus rhamnosus resists low pH (pH is lower than 3), and the lactobacillus rhamnosus resists bile salt (the colony count is 10<7> CFU / mL after the lactobacillus rhamnosus is incubated in 0.3% high-concentration bile salt for 4 hours). The lactobacillus rhamnosus 1.0320 (the ratio of lactobacillus to cells is 1: 1) has very strong regulation capability on a splenic lymphocyte transformation value and NO secreted by peritoneal macrophages, and the immunoregulation capability is obviously higher than that of a reference strain lactobacillus rhamnosus GG (p isless than 0.05). The immunoregulation intensity and concentration of the lactobacillus rhamnosus 1.0320 are positively correlated, when the ratio of lactobacillus rhamnosus 1.0320 to cells is 100: 1,the splenic lymphocyte transformation value is 7.5 times that of a positive control group, and the splenic lymphocyte proliferation index reaches 1 or above.

The invention provides a method for detecting water inherent toxicity by using single cell gel electrophoresis test, which comprises the following steps: performing contaminating treatment on a mouse by using Cr6+ solutions with different concentrations; respectively performing single cell gel electrophoresis test on the splenic lymphocyte of the contaminated mouse so as to obtain olive tail moments under the condition of contamination with the Cr6+ solutions with different concentrations; drawing a standard curve of Cr6+ to olive tail moments; performing contaminating treatment on the mouse with a concentrated and enriched water sample to be detected; measuring an olive tail moment under the condition of the water sample treatment by using the same method; and substituting the olive tail moment in the standard curve to obtain the water toxicity of the water sample to be detected, which is represented by the Cr6+ concentration. By using the method, the Cr6+ is chosen as the standard toxic matter and the quantification evaluation on the water toxicity is realized by using the curve of Cr6+ to the olive tail moment. By using the method provided by the invention, the water inherent toxicity can be measured more directly and accurately, the result is easily unified, the repeatability is good, and the state of water pollution can be judged.

The invention discloses a screening method of immunologic function evaluation indexes of an anthropopathic nose-only rat. The screening method comprises the following steps: taking serum, splenic lymphocyte, splenic lymphocyte culture supernate, peritoneal macrophage and blood of an air breathing rat as a normal contrast group, and taking serum, splenic lymphocyte, splenic lymphocyte culture supernate, peritoneal macrophage and blood of a rat continuously smoking cigarettes through the nose as a smoking group; detecting the multiplication capacities of the lymphocyte, the swallowing conditions of the peritoneal macrophage, the contents of IL-6, TNF-alpha, Ig, IgG and IgE and the differential counting of leukocyte of each group; and finally, screening out five indexes of lymphopoiesis stimulation indexes, the contents of the IL-6, the IgG and the IgE and the differential counting of leukocyte as sensitive and stable evaluation indexes for reflecting the changes of the immunologic functions of the smoking rat. The method is scientific and comprehensive, and the screened evaluation indexes have good sensitive stability.

The invention relates to the field of genetic engineering, in particular to a novel fungal immunomodulatory protein FIP-NHA with antineoplastic activity and a gene thereof. The fungal immunomodulatory protein FIP-NHA according to the invention has an amino acid sequence as shown in SEQ ID NO. 1, and the gene fip-nha for coding the fungal immunomodulatory protein has a nucleotide sequence as shownin SEQ ID NO. 2. The fungal immunomodulatory protein FIP-NHA provided by the invention has the effects on promoting splenic lymphocyte division, increasing synthesis of interleukin 2, and obviously inhibiting proliferation of three tumor cells including hepatoma cell HepG2, gastric cancer cell MGC823 and leukemia cell HL60, therefore, the fungal immunomodulatory protein FIP-NHA as a novel antineoplastic biological agent can be widely used in the fields of health products and biological medicines.

The invention relates to a compound radix codonopsis total saponins and immunopolysaccharides nano emulsion composition and a preparation method thereof. The nano emulsion composition provided by the invention is an oil in water type nano emulsion, has particle sizes between 1nm and 100nm, and is prepared from the following ingredients of three traditional Chinese medicinal active ingredients (radix codonopsis total saponins, pachyman and a radix glycyrrhizae polysaccharide), a surfactant, a cosurfactant, an oil phase and distilled water. The preparation method of the nano emulsion provided by the invention is simple and feasible; a device is easy to control; the product quality is easy to control; the particle size of a liquid drop is small; the solubility and the stability of a medicine can be improved; the proliferation activity of a splenic lymphocyte of an immunocompromised mouse can be improved. The nano emulsion composition provided by the invention can be used for obviously improving the immunoregulatory activity of the three traditional Chinese medicinal active ingredients, and has the potential of developing an immunopotentiator, so as to promote the development and the utilization of a traditional Chinese medicinal resource and an active ingredient thereof.

The invention relates to a traditional Chinese medicine patch for the prevention and early-stage curing of bronchial asthma, and the treatment of a plurality of respiratory diseases and megrims, characterized in that the traditional Chinese medicine patch comprises, based on the weight percentage, 57 to 70 % of peach seed, 12 to 25 % of cape jasmine, 6 to 8 % of almond, and 5 to 10% of pepper. The invention has the advantages that the traditional Chinese medicine patch is mainly used for treating bronchial asthma, can cure the bronchial asthma of children at the age of below 12, and can be used in the outbreaking or catabatic period. The traditional Chinese medicine patch has the efficacy of diminishing inflammation, invigorating blood circulation, removing blood stasis, clearing away cold, relieving cough and calming panting. The traditional Chinese medicine patch can promote the synthesis of the alveolar surfactant, protect the pulmonary function to improve the lesion tissues, and can stimulate the proliferation of blood vessel endothelial cells to restore the endangium. The traditional Chinese medicine patch has the antiallergic effect, can inhibit the antiserum reaction of allergic antibody of the skin, reduce the pigment seepage and alleviate the airway obstruction. The traditional Chinese medicine patch can enhance the proliferation and conversion of T lymphocyte of spleen of a body, and improve the autoimmunity.

The invention discloses a new application of the antitumor effect of a Miao ethnomedicine psammosilene tunicoids, and simultaneously discloses a preparation method and preparation of the pharmaceutical part of psammosilene tunicoids with the antitumor activity. The preparation method mainly comprises the steps of: extracting by ethanol, concentrating, extracting by n-butyl alcohol, purifying by macroporous absorption resin, and the like to obtain the total saponins of psammosilene tunicoids (TSPT). The total saponins are used as raw materials to prepare clinical commonly used pharmaceutical preparations such as tablets, capsules, injections and the like. A method of pharmacodynamic evaluation both in vivo and in vitro is adopted, wherein shown by in vitro tests, the TSPT has stronger inhibitory actions on 6 tumor cells of stomach cancer, liver cancer, colon cancer, ovarian cancer, breast cancer and melanoma, but has unobvious inhibition on the normal splenic lymphocyte; shown by integral animal in vivo experimental results, the TSPT has an inhibition rate as high as 72% on S180 solid tumors and has high action valence, but has small influence on the body weight of mice; and compared with a positive drug cis-platinum, the TSPT has lower side effect. Shown by the experimental results, the TSPT has strong anticancer valence, low side effect and the advantage of original innovation.

The invention discloses an epigynum auritum pregnane glycoside compound and application thereof in preparation of immunosuppressive drugs. An experiment result shows that the compound has strong activity of suppressing proliferation of splenic lymphocytes. The invention provides a leading compound for research on a new immunosuppressor, and facilitates development and utilization of plant medicinal resources.

The invention relates to the technical field of biological food, and provides exopolysaccharide produced by lactobacillus plantarum 589 in order to further protect the performance of lactobacillus plantarum 589, and the exopolysaccharide has the effect of promoting splenic lymphocyte proliferation. And the exopolysaccharide is obtained by culturing in an MRS liquid culture medium after activating.According to the invention, the performance of the lactobacillus plantarum 589 is deeply expanded, the exopolysaccharide produced by the lactobacillus plantarum 589 and the method for producing the exopolysaccharide at high yield are provided, and the yield of the exopolysaccharide reaches about 580mg / L; the lactobacillus plantarum 589 and derivatives thereof can promote proliferation of spleniclymphocytes; exopolysaccharide produced by the lactobacillus plantarum 589 has a low dosage concentration of only 1 [mu]g / mL for promoting splenic lymphocyte proliferation, and the lactobacillus plantarum 589 also has a low dosage concentration of only 1x10<7> CFU for promoting splenic lymphocyte proliferation.